AOD-9604 and Bupropion Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up

Patients pursuing medical weight management often use multiple agents with complementary mechanisms. AOD-9604 is a synthetic peptide corresponding to amino acids 176-191 of human growth hormone, investigated for its lipolytic properties without the diabetogenic or growth-promoting effects of full-length GH [1]. Bupropion, an aminoketone-class norepinephrine-dopamine reuptake inhibitor (NDRI), carries an FDA-approved indication for weight management when combined with naltrexone (Contrave) and is frequently prescribed off-label as monotherapy for patients who also need antidepressant coverage [2].

The Clinical Scenario

A patient on bupropion 300 mg XL daily for major depressive disorder asks about adding subcutaneous AOD-9604 to accelerate fat loss. This scenario is increasingly common in telehealth and compounding-pharmacy settings.

Why Clinicians Should Pay Attention

Neither agent has a published interaction study with the other. The absence of data is not the same as the absence of risk. A structured pharmacologic analysis is the best tool available for guiding clinical decisions when direct evidence does not exist.

Pharmacokinetic Analysis: Do These Drugs Interfere With Each Other's Metabolism?

The short answer is almost certainly no. The metabolic pathways of AOD-9604 and bupropion do not overlap in any meaningful way, making a classic pharmacokinetic interaction unlikely.

AOD-9604 Metabolism

AOD-9604 is a 16-amino-acid peptide. Like other small peptides, it is degraded by ubiquitous peptidases and proteases in plasma and tissue rather than by cytochrome P450 enzymes in the liver [1]. It does not bind plasma proteins to a clinically significant degree. Renal filtration of peptide fragments is the primary elimination route. No CYP induction or inhibition has been attributed to AOD-9604 in preclinical or early-phase clinical work.

Bupropion Metabolism

Bupropion undergoes extensive hepatic metabolism, primarily via CYP2B6 to its active metabolite hydroxybupropion [3]. Threohydrobupropion and erythrohydrobupropion are formed through carbonyl reduction. Bupropion is itself a potent inhibitor of CYP2D6, which is clinically relevant for co-administered drugs cleared through that isoenzyme (e.g., metoprolol, tamoxifen, codeine) [3]. Since AOD-9604 is not a CYP2D6 substrate, this inhibition carries no consequence for the peptide's disposition.

P-glycoprotein and Transporter Considerations

Bupropion has weak interactions with P-glycoprotein (P-gp) efflux transport. AOD-9604, as a hydrophilic peptide, is not a known P-gp substrate. No transporter-mediated interaction is expected.

Pharmacodynamic Considerations: Where Overlap Exists

The pharmacodynamic picture deserves more attention than the pharmacokinetic one. Both agents influence energy balance, appetite signaling, and neurochemical pathways that warrant monitoring.

Appetite and Weight Effects

AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue through a mechanism believed to involve the beta-3 adrenergic receptor pathway, though the full signaling cascade remains under investigation [1]. Bupropion increases synaptic norepinephrine and dopamine, which suppresses appetite centrally via hypothalamic pro-opiomelanocortin (POMC) neuron activation [4]. The combination could produce additive anorectic effects. Patients should be counseled to maintain adequate caloric intake (generally not below 1,200 kcal/day for women or 1,500 kcal/day for men) and to report unintended rapid weight loss exceeding 1 kg per week.

Seizure Threshold

Bupropion carries a well-documented, dose-dependent seizure risk. The FDA label for bupropion SR reports an incidence of approximately 0.1% (1/1,000) at doses up to 300 mg/day and roughly 0.4% (4/1,000) at the maximum dose of 450 mg/day [3]. Risk factors that lower the threshold include eating disorders, abrupt benzodiazepine or alcohol withdrawal, concurrent use of other seizure-threshold-lowering agents, and electrolyte abnormalities.

AOD-9604 has not been reported to affect seizure threshold in any preclinical or clinical study. Aggressive caloric restriction or electrolyte disturbances from rapid weight loss could indirectly lower the threshold in a patient already on bupropion.

Cardiovascular Overlap

Bupropion modestly increases heart rate and blood pressure in some patients through noradrenergic activity [3]. Growth hormone fragments, including AOD-9604, have not demonstrated consistent hemodynamic effects in published trials, but the beta-adrenergic signaling hypothesis raises a theoretical concern. Blood pressure monitoring at baseline and at 4-week intervals is a reasonable precaution.

Risk Stratification Framework for Co-Administration

Not every patient combining these agents carries the same level of risk. A tiered approach helps clinicians make individualized decisions.

Low-Risk Profile

Patients with no history of seizures, no active eating disorder, stable bupropion dose for 8 or more weeks, BMI between 27 and 35, normal electrolytes, and no additional seizure-threshold-lowering medications. These patients can generally proceed with standard AOD-9604 dosing (typically 250-300 mcg subcutaneously daily in compounding protocols) alongside their existing bupropion regimen.

Moderate-Risk Profile

Patients on bupropion 450 mg/day, those with a remote history of a single provoked seizure, or those concurrently taking tramadol, systemic corticosteroids, theophylline, or fluoroquinolones. For this group, a lower starting dose of AOD-9604 (150 mcg/day), closer follow-up at 2-week intervals, and a basic metabolic panel at baseline are appropriate.

High-Risk Profile

Patients with active bulimia or anorexia nervosa, unprovoked seizure history, bupropion combined with other NDRI or stimulant agents, or severe hepatic impairment (which raises bupropion and hydroxybupropion levels unpredictably). Co-administration should be avoided or deferred until the risk factor is resolved.

Monitoring Protocol When Using Both Agents

A structured monitoring plan reduces uncertainty and catches problems early.

Baseline Assessments

Before initiating AOD-9604 in a patient on bupropion, obtain a complete metabolic panel (including glucose, electrolytes, and creatinine), fasting lipid panel, body composition measurement (DEXA or bioimpedance), blood pressure, heart rate, and a validated depression screening tool such as the PHQ-9 [5].

Ongoing Monitoring

At weeks 4, 8, and 12, reassess weight, blood pressure, heart rate, mood (PHQ-9), and any new neurologic symptoms. A repeat metabolic panel at week 8 checks for electrolyte shifts that could compound seizure risk. After 12 weeks, if the combination is well tolerated, monitoring can shift to standard quarterly visits.

Red Flags That Warrant Discontinuation

Stop AOD-9604 and reassess if the patient reports any seizure-like episode (tonic-clonic movements, loss of consciousness, post-ictal confusion), weight loss exceeding 1.5 kg per week for two consecutive weeks, new-onset palpitations or sustained resting heart rate above 100 bpm, or worsening depression or suicidal ideation (which could reflect excessive caloric restriction or a pharmacodynamic mood interaction).

What the FDA Labels Tell Us

The bupropion prescribing information (revised 2023) provides an extensive drug interaction section organized by CYP isoenzyme [3]. It warns specifically about CYP2D6 substrates and recommends dose reductions for drugs like metoprolol when co-prescribed. No peptide agents are mentioned.

AOD-9604 does not have an FDA-approved label. It is available through 503A compounding pharmacies and is classified by the FDA as a bulk drug substance under evaluation. The Therapeutic Goods Administration (TGA) in Australia granted it GRAS (Generally Recognized as Safe) status for use as a food ingredient, but this designation does not extend to injectable formulations or to the U.S. Regulatory context [6].

Compounding Quality Matters

Because AOD-9604 is not manufactured under an NDA or ANDA, product quality depends entirely on the compounding pharmacy. Patients should confirm their pharmacy holds current state board licensure and preferably PCAB (Pharmacy Compounding Accreditation Board) accreditation. Contaminated or mislabeled peptide products introduce unpredictable variables that no interaction analysis can account for.

Clinical Evidence: What Exists and What Does Not

No randomized controlled trial, case series, or even case report has examined the specific combination of AOD-9604 with bupropion. The interaction analysis above is built entirely from first principles: known pharmacology, metabolic pathways, and extrapolation from related compounds.

AOD-9604 Clinical Data

A Phase IIb trial conducted by Metabolic Pharmaceuticals (now Calzada Ltd.) enrolled 300 obese adults randomized to oral AOD-9604 (1 mg, 5 mg, or 25 mg daily) or placebo for 12 weeks. The primary endpoint of mean weight change did not reach statistical significance in any dose arm, though the 1 mg group showed a trend toward greater fat loss by DEXA [1]. Subcutaneous formulations used in current compounding practice were not tested in this trial, complicating dose extrapolation.

Bupropion Weight-Loss Data

The Contrave (bupropion/naltrexone) approval program included four Phase III trials collectively enrolling over 4,500 patients. The COR-I trial (N=1,742) demonstrated 6.1% mean weight loss with bupropion 360 mg/naltrexone 32 mg versus 1.3% with placebo at 56 weeks [7]. Bupropion monotherapy produces more modest weight effects, typically 2-3% beyond placebo at 6 months.

The Gap

No study has tested whether adding a lipolytic peptide to an NDRI antidepressant produces additive, synergistic, or antagonistic weight outcomes. This is a gap that only prospective clinical research can fill.

Dose-Adjustment Guidance

No dose adjustment of either drug is pharmacokinetically required based on available evidence.

Bupropion Dose Considerations

Bupropion dosing should follow standard prescribing guidelines: start at 150 mg SR daily, titrate to 150 mg SR twice daily after 3-4 days if tolerated, with a maximum of 200 mg SR per single dose and 450 mg/day total [3]. Do not increase the bupropion dose specifically to augment weight loss when adding AOD-9604.

AOD-9604 Dose Considerations

Compounding protocols commonly use 250-300 mcg subcutaneously once daily, typically administered in the morning on an empty stomach. In moderate-risk patients (see risk stratification above), starting at 150 mcg/day and titrating to the full dose over 2 weeks provides an additional safety margin. No evidence supports doses above 300 mcg/day for improved efficacy.

Patient Counseling Points

Patients combining these agents need clear expectations.

What to Tell Your Prescriber

Any patient considering AOD-9604 should disclose all current medications, including bupropion, to both their peptide prescriber and their psychiatrist or primary care physician. Fragmented care across telehealth platforms increases the risk of missed interactions.

Injection Technique and Timing

AOD-9604 is typically injected subcutaneously into the abdominal fat pad. There is no known timing interaction with oral bupropion, but separating administration by at least 30 minutes avoids any theoretical concern about injection-site blood flow changes affecting oral drug absorption.

Signs to Watch For

Patients should report new tremor, muscle twitching, confusion, rapid heartbeat, extreme appetite loss, or mood changes promptly. These could indicate pharmacodynamic overlap effects requiring dose reduction or discontinuation of one agent.

How Bupropion's CYP2D6 Inhibition Affects Other Co-Medications

While bupropion does not interact with AOD-9604 through CYP2D6, patients on bupropion often take additional medications that are CYP2D6 substrates. Adding AOD-9604 does not change this picture, but clinicians should use the opportunity to audit the full medication list.

Common CYP2D6 substrates affected by bupropion include metoprolol (increased beta-blocker exposure, risk of bradycardia), tamoxifen (reduced conversion to active endoxifen, potentially reduced efficacy), codeine and tramadol (reduced conversion to active metabolites, decreased analgesia), and dextromethorphan (increased exposure, risk of serotonin-like effects) [3]. These interactions exist regardless of AOD-9604 use but warrant review at each prescribing touchpoint.